Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis is a progressive lung disease with a high mortality rate. Because the signaling pathways activated by several tyrosine kinase receptors have been shown to be involved in lung fibrosis, it has been suggested that the inhibition of these receptors may slow the progression of idiopathic pulmonary fibrosis. METHODS: In a 12-month, phase 2 trial, we assessed the efficacy and safety of four different oral doses of the tyrosine kinase inhibitor BIBF 1120 as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Secondary end points included acute exacerbations, quality of life (measured with the St. George's Respiratory Questionnaire [SGRQ]), and total lung capacity. RESULTS: A total of 432 patients underwent randomization to receive one of four doses of BIBF 1120 (50 mg once a day, 50 mg twice a day, 100 mg twice a day, or 150 mg twice a day) or placebo. In the group receiving 150 mg of BIBF 1120 twice a day, FVC declined by 0.06 liters per year, as compared with 0.19 liters per year in the placebo group, a 68.4% reduction in the rate of loss with BIBF 1120 (P = 0.06 with the closed testing procedure for multiplicity correction; P = 0.01 with the hierarchical testing procedure). This dose also resulted in a lower incidence of acute exacerbations, as compared with placebo (2.4 vs. 15.7 per 100 patient-years, P = 0.02) and a small decrease in the SGRQ score (assessed on a scale of 0 to 100, with lower scores indicating better quality of life) as compared with an increase with placebo (-0.66 vs. 5.46, P = 0.007). Gastrointestinal symptoms (which led to more discontinuations in the group receiving 150 mg twice a day than in the placebo group) and increases in levels of liver aminotransferases were more frequent in the group receiving 150 mg of BIBF 1120 twice daily than in the placebo group. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, BIBF 1120 at a dose of 150 mg twice daily, as compared with placebo, was associated with a trend toward a reduction in the decline in lung function, with fewer acute exacerbations and preserved quality of life. (Funded by Boehringer Ingelheim; ClinicalTrials.gov number, NCT00514683 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The Bayesian approach incorporated dynamic borrowing of historical placebo data from several external IPF trials, including the ASCEND, INPULSIS, and TOMORROW studies (Figures E2 and E3).2,3,13”
From Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial (2026) · cites this paper as [13]
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
The St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Self-citationClinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765
Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationBois, R. M. D., Weycker, D., Albera, C., Bradford, W. Z., Costabel, U., Kartashov, A., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201007-1179oc · Cited by 465
Self-citation
Cited by
Items 701–800 of 1,000
Perrotta, F., Chino, V., Allocca, V., D’Agnano, V., Bortolotto, C., Bianco, A., Corsico, A. G., & Stella, G. M. (2022) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2022.2145948 · Cited by 9
Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design
Santermans, E., Ford, P., Kreuter, M., Verbruggen, N., Meyvisch, P., Wuyts, W. A., Brown, K. K., Lederer, D. J., Byrne, A. J., Molyneaux, P. L., et al. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01093-3 · Cited by 8
Self-citationThe future of pharmacological treatment in idiopathic pulmonary fibrosis
Molina‐Molina, M. (2019) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2019.05.012 · Cited by 10
Acute Exacerbation of Idiopathic Pulmonary Fibrosis: Who to Treat, How to Treat
Kulkarni, T., & Duncan, S. R. (2019) · Current Pulmonology Reports · doi:10.1007/s13665-019-00238-7 · Cited by 8
Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
Yamasaki, Y., & Kuwana, M. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1777857 · Cited by 8
Diffuse parenchymal lung disease
Maher, T. M. (2012) · Medicine · doi:10.1016/j.mpmed.2012.03.007 · Cited by 16
Current Treatments in the Management of Idiopathic Pulmonary Fibrosis: Pirfenidone and Nintedanib
Hayton, C., & Chaudhuri, N. (2017) · Clinical Medicine Insights Therapeutics · doi:10.1177/1179559x17719126 · Cited by 10
Older Idiopathic Pulmonary Fibrosis Male Patients Are at a Higher Risk of Nintedanib Dose Reduction
Harari, S. A., Specchia, C., Lipsi, R., Cassandro, R., & Caminati, A. (2020) · Respiration · doi:10.1159/000508667 · Cited by 8
Chang, W., Chen, C.-M., Sheu, C., Liao, S., Hsu, Y., Tsai, M., & Kuo, P. (2020) · Molecules · doi:10.3390/molecules25225458 · Cited by 10
Thalidomide for the Treatment of Cough in Idiopathic Pulmonary Fibrosis
Lechtzin, N., & Horton, M. R. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-6-201303190-00016 · Cited by 8
Rare (pulmonary) disease day: “feeding the breath, energy for life!”
Harari, S. A., Lau, E., Tamura, Y., Cottin, V., Simonneau, G., & Humbert, M. J. C. (2015) · European Respiratory Journal · doi:10.1183/09031936.00221914 · Cited by 8
Safety of IV Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis
LIMPER, A. H. (2017) · CHEST Journal · doi:10.1016/j.chest.2016.12.015 · Cited by 8
Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Kim, D. S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11454-0 · Cited by 8
Self-citationBouros, D., Daniil, Z., Papakosta, D., Antoniou, K. M., Markopoulou, K., Kolilekas, L., Konstantopoulos, G., Papiris, S., & on behalf of the INDULGE IPF Study Group (2018) · Respiration · doi:10.1159/000487244 · Cited by 7
Mangiferin Against Respiratory Diseases: Pharmacological Targets and Prospects
Ahmed, K. A., Afrin, N., Ghosh, P., Heya, I. A., Akash, S. R., Moni, A., Islam, M. N., Hossain, M. G., Sinopoli, A., Hannan, M. A., et al. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70163 · Cited by 7
Assayag, D., Adegunsoye, A., Khor, Y. H., Bonella, F., Borie, R., Buendía-Roldán, I., Chaudhuri, N., Gibson, K. F., Johannson, K. A., Kaminski, N., et al. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202509-2336st · Cited by 7
Wang, H., Tsai, S., Lin, Y.-C., Hou, J.-U., & Chao, C.-H. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-02947-5 · Cited by 9
Hozumi, H., Miyashita, K., Nakatani, E., Inoue, Y., Yasui, H., Suzuki, Y., Karayama, M., Furuhashi, K., Enomoto, N., Fujisawa, T., et al. (2024) · Respiratory Research · doi:10.1186/s12931-024-02922-y · Cited by 10
Chong, W. H., Agrawal, D., Tan, Z. Y., Venkateswaran, S., Tan, A. Y. Y., Tan, C. Y., Ling, N. C. A., & Tay, N. S. W. T. (2024) · Heart & Lung · doi:10.1016/j.hrtlng.2024.07.010 · Cited by 7
Zheng, H., Li, J., & Leung, S. S. Y. (2024) · Biomaterials Advances · doi:10.1016/j.bioadv.2024.214084 · Cited by 7
Avdeev, S. N., Ananyeva, L. P., Валерьевич, Ж. Е., Zonova, E. V., Клименко, А. А., KONEVA, O. A., Lila, A. M., Pershina, E. S., Стремоухов, А. А., Terpigorev, S. A., et al. (2020) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2020-1-125-128 · Cited by 7
Diagnosis of interstitial lung diseases: from Averill A. Liebow to artificial intelligence
Yi, E. S., Wawryko, P., & Ryu, J. H. (2024) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2023.11.17 · Cited by 7
Inchingolo, R., Condoluci, C., Smargiassi, A., Mastrobattista, A., Boccabella, C., Comes, A., Golfi, N., & Richeldi, L. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1383382 · Cited by 7
Self-citationImatinib may reduce chemotherapy-induced pneumonitis. A report on four cases from the SWENOTECA
Langberg, M., Berglund-Nord, C., Cohn-Cedermark, G. E., Haugnes, H. S., Tandstad, T., & Langberg, C. W. (2018) · Acta Oncologica · doi:10.1080/0284186x.2018.1479072 · Cited by 7
Xie, X., Guo, B., Lin, X., Qin, Y., Ouyang, M., Li, S., & Zhou, C. (2019) · Angiogenesis · doi:10.1007/s10456-019-09673-1 · Cited by 7
The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease
Sarkar, P., Avram, C., & Chaudhuri, N. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1784730 · Cited by 8
Kirsten, D. K., de Vries, U., Costabel, U., Koschel, D., Bonella, F., Günther, A., Behr, J., Claussen, M., Schwarz, S., Prasse, A., et al. (2021) · Pneumologie · doi:10.1055/a-1579-7618 · Cited by 7
Self-citationΤzouvelekis, Α., & Bouros, D. E. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201301-0072le · Cited by 7
Insights into idiopathic pulmonary fibrosis in the real world
Cottin, V., & Wuyts, W. A. (2015) · European Respiratory Journal · doi:10.1183/09031936.00036815 · Cited by 8
Fibroblast heterogeneity in pulmonary fibrosis: a new target for therapeutics development?
Tsoyi, K., & Rosas, I. O. (2024) · European Respiratory Journal · doi:10.1183/13993003.02188-2023 · Cited by 8
Live-cell imaging of human liver fibrosis using hepatic micro-organoids
Guan, Y., Fang, Z., Hu, A., Roberts, S., Wang, M., Ren, W., Johansson, P. K., Heilshorn, S. C., Enejder, A., & Peltz, G. (2025) · JCI Insight · doi:10.1172/jci.insight.187099 · Cited by 6
Effects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosis
Jenkins, R. G., Cottin, V., Nishioka, Y., Noth, I., White, E. S., Ittrich, C., Diefenbach, C., Rohr, K. B., Selman, M., & Maher, T. M. (2024) · ERJ Open Research · doi:10.1183/23120541.00558-2023 · Cited by 6
Self-citationTakuma, S., Hozumi, H., Miyashita, K., Inoue, Y., Yasui, H., Suzuki, Y., Karayama, M., Furuhashi, K., Enomoto, N., Fujisawa, T., et al. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108185 · Cited by 6
Shi, T., Jin, M., Li, H., Ye, Y., Ma, X., Yang, Q., & Zhu, J. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126088 · Cited by 7
Nili, M., Epstein, A. J., Nunag, D., Olson, A. L., & Borah, B. J. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-02929-7 · Cited by 6
Behr, J., Bonella, F., Frye, B. C., Günther, A., Hagmeyer, L., Henes, J., Klemm, P., Koschel, D., Kreuter, M., Leuschner, G., et al. (2024) · Respiration · doi:10.1159/000540856 · Cited by 13
Self-citationIkeda, S., Sekine, A., Baba, T., Yamakawa, H., Morita, M., Kitamura, H., & Ogura, T. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-016-0201-9 · Cited by 6
Systemic sclerosis phase III clinical trials: Hope on the horizon?
Aringer, M., & Denton, C. P. (2018) · Journal of Scleroderma and Related Disorders · doi:10.1177/2397198318775353 · Cited by 6
Chikina, S. Y., Cherniak, A. V., Мержоева, З. М., Tyurin, I. E., Трушенко, Н. В., Proshkina, A. A., Ataman, K. S., & Avdeev, S. N. (2023) · Life · doi:10.3390/life13020435 · Cited by 7
Recent Advances in the Treatment of Interstitial Lung Diseases
Bang, A. A., Bang, S., Bang, A., Acharya, S., & Shukla, S. (2023) · Cureus · doi:10.7759/cureus.48016 · Cited by 6
Pennati, F., Belenkov, S., Buccardi, M., Ferrini, E., Sverzellati, N., Villetti, G., Aliverti, A., & Stellari, F. F. (2024) · iScience · doi:10.1016/j.isci.2024.109262 · Cited by 6
Ayano, M., Tsubouchi, K., Suzuki, K., Kimoto, Y., Arinobu, Y., Akashi, K., Horiuchi, T., Okamoto, I., & Niiro, H. (2024) · Scandinavian Journal of Rheumatology · doi:10.1080/03009742.2024.2327159 · Cited by 7
Pharmacological treatment in Idiopathic Pulmonary Fibrosis: current issues and future perspectives
Vancheri, C., Sciacca, E., Muscato, G., Spicuzza, L., Fruciano, M., Gili, E., Sambataro, G., Palmucci, S., & Libra, A. (2024) · Multidisciplinary Respiratory Medicine · doi:10.5826/mrm.2024.982 · Cited by 14
Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Viswanathan, V. K., Ghoshal, A. G., Mohan, A., Patil, K., Bhargave, C., CHOUDHARI, S. Y., & Mehta, S. C. (2024) · Pulmonary Therapy · doi:10.1007/s41030-024-00271-1 · Cited by 9
Mao, S., Yu, N. H., Wang, W., Mao, Y., Du, Y., Zhao, Q., Gu, X., & Kang, J. (2025) · Cell Biology and Toxicology · doi:10.1007/s10565-025-10031-9 · Cited by 8
Influence of Idiopathic Pulmonary Fibrosis Progression on Healthcare Resource Use
Diamantopoulos, A., Maher, T. M., Schoof, N., Esser, D., & LeReun, C. (2018) · PharmacoEconomics - Open · doi:10.1007/s41669-018-0085-0 · Cited by 6
Higo, H., Miyahara, N., Taniguchi, A., Senoo, S., Itano, J., Watanabe, H., Oda, N., Kayatani, H., Ichikawa, H., Shibayama, T., et al. (2020) · Respiratory Investigation · doi:10.1016/j.resinv.2019.12.007 · Cited by 9
Inomata, M., Jo, T., Kuse, N., Awano, N., Tone, M., Yoshimura, H., Moriya, A., Bae, Y., Terada, Y., Furuhata, Y., et al. (2020) · Respiratory Investigation · doi:10.1016/j.resinv.2020.07.001 · Cited by 6
Boleto, G., Avouac, J., & Allanore, Y. (2022) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x211066686 · Cited by 6
Kerget, B., Çil, G., Araz, Ö., Alper, F., & Akgün, M. (2023) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2022.12.019 · Cited by 10
Idiopathic Pulmonary Fibrosis and Antifibrotic Treatments: Focus on Experimental Studies
Lunardi, F., Pezzuto, F., Vuljan, S. E., & Calabrese, F. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0080-ra · Cited by 6
Mohning, M. P., Downey, G. P., Cosgrove, G. P., & Redente, E. F. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54431-3.00003-2 · Cited by 122
Davis, S., Rafia, R., Carroll, C., Hamilton, J., & Essat, M. (2018) · PharmacoEconomics · doi:10.1007/s40273-018-0727-1 · Cited by 6
Use of nintedanib in patients with idiopathic pulmonary fibrosis: Initial Indian experience
Mullerpattan, J., Porwal, S., Sarkar, T., Wagh, H., & Udwadia, Z. (2019) · Lung India · doi:10.4103/lungindia.lungindia_195_19 · Cited by 6
Nintedanib-Induced Colitis Treated Effectively With Budesonide
Amini, A., Koury, E., & Chahla, E. J. (2020) · Cureus · doi:10.7759/cureus.9489 · Cited by 7
Martusewicz-Boros, M. M., & Górska, K. (2020) · Advances in respiratory medicine · doi:10.5603/arm.a2020.0190 · Cited by 7
Wang, Y., Gong, X., Hu, Y., Yi, Q., Zhang, Q., Miao, L., & Zhou, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.873709 · Cited by 7
Therapie der Lungenfibrose: Neue Substanzen, neue Interventionen
Costabel, U., & Bonella, F. (2011) · Der Internist · doi:10.1007/s00108-011-2926-0 · Cited by 6
Self-citationWarfarin in Idiopathic Pulmonary Fibrosis: Friend or Foe, Is It a Matter of Genes and Heparin?
Τzouvelekis, Α., Margaritopoulos, G. A., Loukides, S., & Bouros, D. E. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.187.2.213 · Cited by 6
Clinical trials in idiopathic pulmonary fibrosis: a framework for moving forward
Lederer, D. J. (2013) · European Respiratory Journal · doi:10.1183/09031936.00092713 · Cited by 7
Screening for Lung Cancer and Idiopathic Pulmonary Fibrosis: Killing Two Birds with One Stone
Cordier, J.-F., Cottin, V., Khouatra, C., & Revel, D. (2014) · Radiology · doi:10.1148/radiol.13131866 · Cited by 6
Elborn, J. S., Ramsey, B. W., Wainwright, C. E., & Boyle, M. (2015) · Thorax · doi:10.1136/thoraxjnl-2015-207611 · Cited by 6
Another Weapon in the Battle against Idiopathic Pulmonary Fibrosis?
Wilson, C. L., & Hung, C. F. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0387ed · Cited by 6
Paul, S., & Colson, Y. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-24126-7.00011-9 · Cited by 6
Kim, G. H. J., Zhang, X., Brown, M. S., Poole, L., & Goldin, J. G. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-094559 · Cited by 8
Suzuki, K., Akiyama, M., Shimanuki, K., Fukui, H., & Kaneko, Y. (2025) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2025.152891 · Cited by 5
A safety evaluation of pirfenidone for the treatment of idiopathic pulmonary fibrosis
Anderson, A., Shifren, A., & Nathan, S. D. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1187129 · Cited by 5
Disease progression in idiopathic pulmonary fibrosis under anti-fibrotic treatment.
Çilli, A., & Üzer, F. (2023) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v40i3.14048 · Cited by 12
Tackling pulmonary fibrosis risks in post-COVID-19: cutting-edge treatments
Duong‐Quy, S., Hai, C. N., Huynh-Anh, T., & Nguyen‐Nhu, V. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2438322 · Cited by 5
Idiopathic Pulmonary Fibrosis: The Epidemiology and Natural History of Disease
Tourin, O., Swigris, J. J., & Olson, A. L. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_2 · Cited by 5
Clinical highlights from the 2011 ERS Congress in Amsterdam
Spruit, M. A., Chavannes, N. H., Herth, F. J. F., Poletti, V. E., Ley, S., Burghuber, O. C., Clini, E. M., & Cottin, V. (2012) · European Respiratory Journal · doi:10.1183/09031936.00217111 · Cited by 5
Li, M., Wang, S., Fan, M., Li, Z., & Huang, Y. (2006) · PubMed · Cited by 7
New Treatments for Idiopathic Pulmonary Fibrosis
Meyer, K. C., & Modi, D. (2016) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0000000000000166 · Cited by 5
Li, X., Pan, J., Ma, Y., Ren, Y., & Gao, B. (2021) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-21-255 · Cited by 5
Rodríguez‐Nieto, M. J., Cano-Jiménez, E., Ortíz, A. D. R., Villar, A., Morros, M., Ramón, A., & Armengol, S. (2023) · PharmacoEconomics · doi:10.1007/s40273-023-01278-3 · Cited by 6
Transbronchial Cryobiopsy in Interstitial Lung Disease: Advantageous Costs to Benefits Ratio
Montero, Á. (2015) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2015.02.033 · Cited by 5
Fibrosis pulmonar idiopática: un reto para la atención primaria
Molina, J., Trigueros, J. A., Quintano, J. A., Mascarós, E., Xaubet, A., & Ancochea, J. (2014) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2014.02.001 · Cited by 5
Raghu, G., Rochwerg, B. N., Zhang, Y., García, C. Á., Azuma, A., Behr, J., Brożek, J., Collard, H. R., Cunningham, W. E., Homma, S. A., et al. (2015) · Cited by 9
Self-citationSevere idiopathic pulmonary fibrosis: A clinical approach
Lipsi, R., Mazzola, D., Caminati, A., Elia, D., Lonati, C., & Harari, S. A. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.01.014 · Cited by 5
Antifibrotic therapy of idiopathic pulmonary fibrosis: efficiency / safety ratio
Авдеев, С. Н., & Трушенко, Н. В. (2018) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2018-15-131-136 · Cited by 5
Yamamura, K., Hara, J., Watanabe, S., Kobayashi, T., Kase, K., Takeda, Y., Terada, N., Koba, H., Tambo, Y., Ohkura, N., et al. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-23-1443 · Cited by 6
Medical Therapy of Fibrostenotic Crohn's Disease
Siegmund, B. (2015) · Visceral Medicine · doi:10.1159/000435868 · Cited by 5
Wilcox, M. E., Rivera, M. P., Sassoon, C. S. H., Ware, L. B., Wunsch, H., & Herridge, M. S. (2012) · Proceedings of the American Thoracic Society · doi:10.1513/pats.201206-033tt · Cited by 5
MicroRNAs in Idiopathic Pulmonary Fibrosis
Pandit, K. V., & Kaminski, N. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800553-8.00007-x · Cited by 5
Chronic Lower Respiratory Tract Diseases
Pérez‐Padilla, R., Marks, G. B., Wong, G., Bateman, E. D., & Jarvis, D. (2017) · World Bank, Washington, DC eBooks · doi:10.1596/978-1-4648-0518-9_ch15 · Cited by 8
Primary Endpoints in Phase 3 Clinical Trials in Idiopathic Pulmonary Fibrosis: One Step at a Time
Spagnolo, P., Luppi, F., Maher, T. M., Wuyts, W. A., & Grutters, J. C. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201209-1755le · Cited by 5
Pulmonary fibrosis in connective tissue disease (CTD): urgent challenges and opportunities
Fischer, A., & Donnelly, S. C. (2017) · QJM · doi:10.1093/qjmed/hcx140 · Cited by 5
Maher, T. M., Hamblin, M. J., Choi, W.-I., Case, A. H., Tomos, I. P., Tzouvelekis, A. E., Shore, J. E., Bergna, M. A., Golod, D., Elenko, E., et al. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag155 · Cited by 4
Matics, Z., Bardóczi, A. B., Galkó, C., Szabó, B., Gede, N., Molnár, Z., Duray, G. Z., Turan, C., Hegyi, P., Horváth, G., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102966 · Cited by 4
Kim, B., Han, K., Park, J., Kim, B., Han, D., Chung, S. J., Kang, H. K., Kim, S., Park, M. S., Sohn, J. W., et al. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666251406024 · Cited by 4
Perreault, A., Harper, K., Lebel, M., Charbonneau, M., Adam, D., Brochiero, E., Cantin, A. M., Leduc, M., Gagnon, L., & Dubois, C. M. (2022) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2022-0037ma · Cited by 7
Chronic Respiratory Disease: COPD, IPF
Incalzi, R. A., & Fimognari, F. L. (2023) · Practical issues in geriatrics · doi:10.1007/978-3-031-28061-0_22 · Cited by 4
Pharmacological Treatment of Idiopathic Pulmonary Fibrosis
Spagnolo, P., Luppi, F., Montanari, G., & Richeldi, L. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_14 · Cited by 4
Self-citationThe Keys to Making a Confident Diagnosis of IPF
Wadhwa, A., & Flaherty, K. R. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_5 · Cited by 4
Self-citationManagement and support of patients with fibrosing interstitial lung diseases
Barbera, T., Davila, L., & Patel, N. M. (2021) · The Nurse Practitioner · doi:10.1097/01.npr.0000743332.64602.aa · Cited by 4
Hayakawa, T., Sekihara, K., Tajiri, T., Shibata, M., Fujisawa, T., Suda, T., Shiiya, N., & Funai, K. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.11.018 · Cited by 5
Li, F., Chen, Y., Zhang, G., Liu, M., Zeng, H., & Dai, H. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03425-8 · Cited by 5
Steiner, C. A., & Higgins, P. (2018) · Springer eBooks · doi:10.1007/978-3-319-90578-5_23 · Cited by 6
LaCamera, P. P., Limb, S. L., Haselkorn, T., Morgenthien, E. A., Stauffer, J. L., & Wencel, M. L. (2019) · Chronic Respiratory Disease · doi:10.1177/1479973119879678 · Cited by 4
The phosphodiesterase 4 inhibitor AA6216 suppresses activity of fibrosis-specific macrophages
Matsuhira, T., Nishiyama, O., Tabata, Y., Kurashimo, S., Sano, H., Iwanaga, T., & Tohda, Y. (2021) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2021.101118 · Cited by 7
Metadata
- Authors
- Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., Brun, M., Gupta, A., Juhel, N., Klüglich, M., & du Bois, R. M.
- Affiliations
- University of Modena and Reggio Emilia (IT)
- Ruhrlandklinik (DE)
- Asan Medical Center (KR)
- Royal Brompton Hospital (GB)
- Michigan Medicine (US)
- Duke Medical Center (US)
- University of Washington (US)
- Boehringer Ingelheim (France) (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-09-22
- Volume
- 365
- Issue
- 12
- Pages
- 1079-1087
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2152974152
- Cited by
- 1,157
- References
- 22
- Citations by year
- 2026: 32 · 2025: 50 · 2024: 79 · 2023: 74 · 2022: 83 · 2021: 86 · 2020: 73 · 2019: 72 · 2018: 91 · 2017: 102 · 2016: 88 · 2015: 100 · 2014: 71 · 2013: 80 · 2012: 61
- FWCI
- 60.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- idiopathic pulmonary fibrosis, nintedanib, tyrosine kinase inhibitors, forced vital capacity decline, lung fibrosis progression, acute exacerbation, quality of life, gastrointestinal adverse effects, liver aminotransferases, dose comparison, St George's Respiratory Questionnaire, total lung capacity, drug safety and efficacy
- MeSH terms
- Adult, Aged, Alanine Transaminase, Aspartate Aminotransferases, Enzyme Inhibitors, Female, Humans, Indoles, Liver, Male, Middle Aged, Protein-Tyrosine Kinases, Vital Capacity, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.